14
Jul
2010
Posted in I - Series D, Q - 2Q10, R - NORTH EAST, X - Opthalmology, XX - MA
Inotek Pharmaceuticals (Lexington, MA) a clinical-stage small molecule company focused on age-related macular degeneration, glaucoma, cataract and diabetic retinopathy, closed a $18M Series D financing. Participants include Devon Park Bioventures, Rho Ventures, Care Capital, Pitango Venture Capital, MedImmune Ventures and Bio One Capital.